To specifically determine the extent to which the induction of anti-tumor activity by Compound 182 may be reliant on targeting PTP1B and/or PTPN2 in T cells, we next asked if Compound 182 could repress the growth of AT3-OVA tumors in Rag1–/– (C57BL/6) mice that lack T cells and B cells. This evidence concerns the gene PTPN2 and neoplasm.